Exploring the effects of Saorilao-4 on the gut microbiota of pulmonary fibrosis model rats based on 16S rRNA sequencing

• Published in: Journal of applied microbiology Vol. 135; no. 7
• Main Authors: Song, Xinni, Fu, Xinyue, Niu, Shufang, Wang, Peng, Qi, Jun, Shi, Songli, Chang, Hong, Bai, Wanfu
• Format: Journal Article
• Language: English
• Published: England 02.07.2024
• Subjects: Animals; Bacteria - classification; Bacteria - genetics; Bacteria - isolation & purification; Disease Models, Animal; Feces - microbiology; Gastrointestinal Microbiome - drug effects; Male; Pulmonary Fibrosis - genetics; Pulmonary Fibrosis - microbiology; Rats; Rats, Sprague-Dawley; RNA, Ribosomal, 16S - genetics; 16S rRNA; Saorilao-4; Mongolian medicine; gut microbiota; pulmonary fibrosis
• ISSN: 1365-2672; 1365-2672
• DOI: 10.1093/jambio/lxae178

Pulmonary fibrosis (PF) is a progressive and incurable lung disease for which treatment options are limited. Here, we aimed to conduct an exploratory study on the effects of the Mongolian medicine Saorilao-4 (SRL) on the gut microbiota structure, species abundance, and diversity of a rat PF model as well as the mechanisms underlying such effects. Rat fecal samples were analyzed using 16S rRNA sequencing technology. Bioinformatic and correlation analyses were performed on microbiota data to determine significant associations. SRL substantially attenuated the adverse effects exerted by PF on the structure and diversity of gut microbiota while regulating its alpha and beta diversities. Linear discriminant analysis effect size enabled the identification of 62 differentially abundant microbial taxa. Gut microbiota abundance analysis revealed that SRL significantly increased the relative abundance of bacterial phyla such as Firmicutes and Bacteroidetes. Moreover, SRL increased the proportion of beneficial bacteria, such as Lactobacillus and Bifidobacteriales, decreased the proportion of pathogenic bacteria, such as Rikenellaceae, and balanced the gut microbiota by regulating metabolic pathways. SRL may attenuate PF by regulating gut microbiota. This exploratory study establishes the groundwork for investigating the metagenomics of PF.